Document is current
Any future updates will be listed below
-
Authors
Rajoli, Rajith K. R.
Back, David J.
Rannard, Steve
Meyers, Caren Freel
Flexner, Charles
Owen, Andrew
Siccardi, Marco
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (R24 AI 118397, R24 AI 118397, R24 AI 118397)
- License Information
-
More Information
Article History
First Online: 24 May 2017
Compliance with Ethical Standards
:
: This work was supported by the National Institutes of Health (R24 AI 118397).
: David J. Back receives consulting or advisor fees from Abbvie, Boehringer Ingelheim, Gilead, Janssen, Merck and ViiV. He also receives research funding from Abbvie, Boehringer Ingelheim, BMS, Gilead, Janssen, Merck and ViiV. Steve Rannard receives funding from ViiV and AstraZeneca and has many human immunodeficiency virus nanomedicine patents. Charles Flexner receives consulting or advisor fees from Abbvie, Boehringer Ingelheim, Bristol Myers-Squibb, Gilead and GlaxoSmithKline, Merck and ViiV. Andrew Owen receives research funding from Merck, ViiV Healthcare, Janssen, Pfizer and AstraZeneca, consultancy from Merck and Norgine and is a co-inventor of patents relating to human immunodeficiency virus nanomedicines. Marco Siccardi receives research funding from ViiV and Janssen. Rajith K. R. Rajoli and Caren Freel Meyers have no conflicts of interest to declare.
